Clinical toxicities encountered with paclitaxel (Taxol)
- PMID: 8102012
Clinical toxicities encountered with paclitaxel (Taxol)
Abstract
Although paclitaxel (TAXOL) appears to be one of the most promising antineoplastic agents of the last decade, with demonstrated activity in advanced and refractory ovarian, breast, lung, and head and neck cancers, most clinical oncologists have had little experience with the agent. This is largely the result of the initially limited supply of paclitaxel and other obstacles encountered during early clinical development that restricted the drug's availability to a few investigational centers. Although a high incidence of major hypersensitivity reactions due to the Cremophor EL vehicle used in formulation disrupted and almost terminated the clinical development of paclitaxel, hypersensitivity reactions are no longer a serious problem consequent to the advent of effective premedication regimens and longer administration schemes. Instead, neutropenia is the principal toxicity of paclitaxel. At clinically relevant doses, absolute neutrophil count nadirs are severely depressed in most patients. The duration of severe neutropenia, however, is usually brief; treatment delays for unresolved hematologic toxicity are rare, and absolute neutrophil count nadirs are constant with repetitive dosing, suggesting that neutropenia is not cumulative. Asymptomatic sinus bradycardia has occurred in up to 29% of patients in phase II trials, and other cardiac disturbances, including atrioventricular conduction and bundle branch blocks, ventricular tachycardia, and possible ischemic manifestations, have been reported in approximately 3% of patients. Cardiac disturbances have primarily been noted in studies that used cardiac monitoring to more effectively detect and manage major hypersensitivity reactions. Although sinus bradycardia and conduction blocks appear to represent true toxicities, ventricular tachycardia and ischemic manifestations, which have largely been observed in patients with preexisting cardiac disease, may not be due to paclitaxel. In view of the lack of clinical significance of the cardiac effects and their infrequent occurrence, cardiac monitoring during paclitaxel is not recommended for patients without cardiac risk factors. However, until precise risk factors can be defined, patients with a significant antecedent cardiac history are generally not considered to be good candidates for paclitaxel therapy. Neurotoxicity, characterized principally by peripheral neurosensory manifestations, has generally been of mild to moderate severity, even in heavily pretreated patients at paclitaxel doses < or = 200 mg/m2. However, some patients have developed a severe sensory-motor polyneuropathy at higher doses of paclitaxel (given as a single agent or in combination with cisplatin). Patients with an antecedent peripheral neuropathy or coexisting medical illnesses associated with peripheral neuropathy (such as diabetes mellitus and substantial prior alcohol use) appear to be especially prone to developing peripheral neuropathy.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Sequences of taxol and cisplatin: a phase I and pharmacologic study.J Clin Oncol. 1991 Sep;9(9):1692-703. doi: 10.1200/JCO.1991.9.9.1692. J Clin Oncol. 1991. PMID: 1678780 Clinical Trial.
-
Patient care issues: the management of paclitaxel-related toxicities.Ann Pharmacother. 1994 May;28(5 Suppl):S27-30. doi: 10.1177/10600280940280S507. Ann Pharmacother. 1994. PMID: 7915156 Review.
-
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.Int J Clin Lab Res. 1994;24(1):6-14. doi: 10.1007/BF02592403. Int J Clin Lab Res. 1994. PMID: 7910054 Review.
-
Cardiac disturbances during the administration of taxol.J Clin Oncol. 1991 Sep;9(9):1704-12. doi: 10.1200/JCO.1991.9.9.1704. J Clin Oncol. 1991. PMID: 1678781
-
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.Ann Intern Med. 1989 Aug 15;111(4):273-9. doi: 10.7326/0003-4819-111-4-273. Ann Intern Med. 1989. PMID: 2569287
Cited by
-
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial.Front Med (Lausanne). 2022 Aug 11;9:967964. doi: 10.3389/fmed.2022.967964. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36035422 Free PMC article.
-
HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.PLoS One. 2014 Dec 26;9(12):e115228. doi: 10.1371/journal.pone.0115228. eCollection 2014. PLoS One. 2014. PMID: 25542032 Free PMC article.
-
Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles.Eur J Pharm Biopharm. 2015 May;92:120-9. doi: 10.1016/j.ejpb.2015.02.017. Epub 2015 Mar 7. Eur J Pharm Biopharm. 2015. PMID: 25753197 Free PMC article.
-
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.J Clin Oncol. 2016 Sep 1;34(25):3014-22. doi: 10.1200/JCO.2015.66.2346. Epub 2016 Jun 20. J Clin Oncol. 2016. PMID: 27325863 Free PMC article.
-
Anomalies in the valve morphogenesis of the centric diatom alga Aulacoseira islandica caused by microtubule inhibitors.Biol Open. 2018 Aug 22;7(8):bio035519. doi: 10.1242/bio.035519. Biol Open. 2018. PMID: 30037970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources